Home›Trial›NCT05119907
🔬NCT05119907Phase 2ACTIVE NOT RECRUITING

Study of Sacituzumab Govitecan in Patients With Solid Tumor

Study Summary

The goal of this study is to see how effective the study drug, sacituzumab govitecan-hziy, is in participants with solid tumor.

Conditions
Solid Tumor
Interventions / Drugs
Sacituzumab Govitecan-hziy
View on ClinicalTrials.gov ↗
Sponsor
GILD
Gilead Sciences
Antiviral
F24/100
Study Details
Enrollment53 participants
Primary Completion—
Lead SponsorGilead Sciences
Data Retrieved2026-04-11 02:55:27.113198+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.